Replies to post #131730 on Biotech Values

[DewDiligence]

PFE’s profit share on Enbrel sales in US/Canada is replaced by a declining royalty scheme starting in late 2013 and lasting through 2015, according to AMGN’s JPM webcast.

PFE will retain its full ex-North America rights on Enbrel.